Clene Inc (CLNN)
NASDAQ:CLNN
Want to see CLNN full AI Analyst Report?
CLNN Stock Chart & Stats
$6.31
-$0.20(-3.40%)
At close: 4:00 PM EST
$6.31
-$0.20(-3.40%)
Day’s Range― - ―
52-Week Range$3.25 - $13.50
Previous CloseN/A
Volume48.08K
Average Volume (3M)936.24K
Market Cap
$75.01M
Enterprise Value$83.73M
Total Cash (Recent Filing)$5.94M
Total Debt (Recent Filing)$22.05M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Aug 17, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.25
Shares Outstanding12,778,307
10 Day Avg. Volume122,464
30 Day Avg. Volume936,240
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-3.29
Price to Sales (P/S)289.36
P/FCF Ratio-3.11
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue624.83
Enterprise Value/Gross Profit-343.15
Enterprise Value/Ebitda-3.49
Forecast
1Y Price Target
$32.20Price Target Upside410.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.69
Revenue Forecast (FY)$172.83K
Bulls Say, Bears Say
Bulls Say
Regulatory PathwayFDA feedback that CNM-Au8 data may support accelerated approval and use of neurofilament light as a surrogate creates a durable structural pathway to earlier market access in ALS. If accepted, this can shorten time-to-revenue, reduce development risk versus full approval, and shape confirmatory Phase 3 design.
Non-dilutive R&D SupportReimbursable NIH subaward funding materially offsets R&D costs and validates the program scientifically. This non-dilutive support improves runway and reduces near-term financing dependence while reinforcing external endorsement of CNM-Au8 development and expanded access efforts.
Liability Management & FinancingExtending note maturities and completing a $7M equity offering structurally eases near-term cash obligations and improves liquidity management. Pushing principal to maturity and adding equity funding preserves operating capacity into late 2026/2027 while management pursues regulatory milestones.
Bears Say
High Cash BurnPersistent, large negative operating and free cash flows indicate the company consumes significant cash to fund operations. This structural cash-burn profile necessitates repeated external financing or asset monetization, increasing dilution risk and pressuring strategic flexibility absent near-term revenue or milestone receipts.
Elevated Leverage / Negative EquityNegative shareholders' equity and notable debt create structural balance-sheet weakness, constraining borrowing capacity and increasing refinancing or covenant risk. This elevated leverage raises cost of capital and limits options for strategic investments unless capital structure is materially improved.
Minimal Revenue & Large LossesVery low and declining revenues coupled with multi‑year large operating losses reflect an inability to generate product sales and a cost base far exceeding current receipts. Structurally, this keeps the firm dependent on financing and means commercial viability hinges on successful regulatory approval and later commercialization execution.
Clene News
CLNN FAQ
What was Clene Inc’s price range in the past 12 months?
Clene Inc lowest stock price was $3.25 and its highest was $13.50 in the past 12 months.
What is Clene Inc’s market cap?
Clene Inc’s market cap is $75.01M.
When is Clene Inc’s upcoming earnings report date?
Clene Inc’s upcoming earnings report date is Aug 17, 2026 which is in 74 days.
How were Clene Inc’s earnings last quarter?
Clene Inc released its earnings results on May 14, 2026. The company reported -$0.69 earnings per share for the quarter, missing the consensus estimate of -$0.637 by -$0.053.
Is Clene Inc overvalued?
According to Wall Street analysts Clene Inc’s price is currently Undervalued.
Does Clene Inc pay dividends?
Clene Inc does not currently pay dividends.
What is Clene Inc’s EPS estimate?
Clene Inc’s EPS estimate is -0.37.
How many shares outstanding does Clene Inc have?
Clene Inc has 12,778,307 shares outstanding.
What happened to Clene Inc’s price movement after its last earnings report?
Clene Inc reported an EPS of -$0.69 in its last earnings report, missing expectations of -$0.637. Following the earnings report the stock price went up 8.462%.
Which hedge fund is a major shareholder of Clene Inc?
Currently, no hedge funds are holding shares in CLNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clene Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.20 (410.30% Upside)
$32.20 (410.30% Upside)
Hedge Fund Trend
Increased
By 50.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 26.4%
Last 30 Days ▲ 26.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.79%
12-Months-Change
Fundamentals
Return on Equity
233.93%
Trailing 12-Months
Asset Growth
-14.41%
Trailing 12-Months
Company Description
Clene Inc
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
CLNN Stock 12 Month Forecast
Average Price Target
$32.20
▲(410.30% Upside)
Technical Analysis
Dyadic International
―
Akari Therapeutics
―
Estrella Immunopharma
―
AN2 Therapeutics, Inc.
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
37.89% Insiders
2.96% Mutual Funds
10.26% Other Institutional Investors
46.53% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---